Beatriz Quinchia Johnson1, Ryan Fox, Xia Chen, Susan Thibeault. 1. Division of Otolaryngology-Head and Neck, Department of Surgery, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin, USA.
Abstract
OBJECTIVES/HYPOTHESIS: To determine the effectiveness of bone marrow mesenchymal stem cell (BM-MSC) transplantation in isolation or within a synthetic extracellular matrix (sECM) for tissue regeneration of the scarred vocal fold lamina propria. METHODS: In vitro stability and compatibility of mouse BM-MSC embedded in sECM was assessed by flow cytometry detection of BM-MSC marker expression and proliferation. Eighteen rats were subjected to vocal fold injury bilaterally, followed by 1 month post-treatment with unilateral injections of saline or sECM hydrogel (Extracel; Glycosan BioSystems, Inc., Salt Lake City, UT), green fluorescence protein (GFP)-mouse BM-MSC, or BM-MSC suspended in sECM. Outcomes measured 1 month after treatment included procollagen-III, fibronectin, hyaluronan synthase-III (HAS3), hyaluronidase (HYAL3), smooth muscle actin (SMA), and transforming growth factor-beta 1(TGF-beta1) mRNA expression. The persistence of GFP BM-MSC, proliferation, apoptosis, and myofibroblast differentiation was assessed by immunofluorescence. RESULTS: BM-MSC grown in vitro within sECM express Sca-1, are positive for hyaluronan receptor CD44, and continue to proliferate. In the in vivo study, groups injected with BM-MSC had detectable GFP-labeled BM-MSC remaining and showed proliferation and low apoptotic or myofibroblast markers compared to the contralateral side. Embedded BM-MSC in the sECM group exhibited increased levels of procollagen III, fibronectin, and TGF-beta1. BM-MSC within sECM downregulated the expression of SMA compared to BM-MSC alone and exhibited upregulation of HYAL3 and no change in HAS3 compared to saline. CONCLUSIONS: Treatment of vocal fold scarring with BM-MSC injected in a sECM displayed the most favorable outcomes in ECM production, hyaluronan metabolism, myofibroblast differentiation, and production of TGF-beta1. Furthermore, the combined treatment had no detectable cytotoxicity and preserved local cell proliferation.
OBJECTIVES/HYPOTHESIS: To determine the effectiveness of bone marrow mesenchymal stem cell (BM-MSC) transplantation in isolation or within a synthetic extracellular matrix (sECM) for tissue regeneration of the scarred vocal fold lamina propria. METHODS: In vitro stability and compatibility of mouse BM-MSC embedded in sECM was assessed by flow cytometry detection of BM-MSC marker expression and proliferation. Eighteen rats were subjected to vocal fold injury bilaterally, followed by 1 month post-treatment with unilateral injections of saline or sECM hydrogel (Extracel; Glycosan BioSystems, Inc., Salt Lake City, UT), green fluorescence protein (GFP)-mouse BM-MSC, or BM-MSC suspended in sECM. Outcomes measured 1 month after treatment included procollagen-III, fibronectin, hyaluronan synthase-III (HAS3), hyaluronidase (HYAL3), smooth muscle actin (SMA), and transforming growth factor-beta 1(TGF-beta1) mRNA expression. The persistence of GFP BM-MSC, proliferation, apoptosis, and myofibroblast differentiation was assessed by immunofluorescence. RESULTS: BM-MSC grown in vitro within sECM express Sca-1, are positive for hyaluronan receptor CD44, and continue to proliferate. In the in vivo study, groups injected with BM-MSC had detectable GFP-labeled BM-MSC remaining and showed proliferation and low apoptotic or myofibroblast markers compared to the contralateral side. Embedded BM-MSC in the sECM group exhibited increased levels of procollagen III, fibronectin, and TGF-beta1. BM-MSC within sECM downregulated the expression of SMA compared to BM-MSC alone and exhibited upregulation of HYAL3 and no change in HAS3 compared to saline. CONCLUSIONS: Treatment of vocal fold scarring with BM-MSC injected in a sECM displayed the most favorable outcomes in ECM production, hyaluronan metabolism, myofibroblast differentiation, and production of TGF-beta1. Furthermore, the combined treatment had no detectable cytotoxicity and preserved local cell proliferation.
Authors: K W Liechty; T C MacKenzie; A F Shaaban; A Radu; A M Moseley; R Deans; D R Marshak; A W Flake Journal: Nat Med Date: 2000-11 Impact factor: 53.440
Authors: Dinesh K Chhetri; Christian Head; Elena Revazova; Stephen Hart; Sunita Bhuta; Gerald S Berke Journal: Otolaryngol Head Neck Surg Date: 2004-12 Impact factor: 3.497
Authors: Xiao Zheng Shu; Kaustabh Ghosh; Yanchun Liu; Fabio S Palumbo; Yi Luo; Richard A Clark; Glenn D Prestwich Journal: J Biomed Mater Res A Date: 2004-02-01 Impact factor: 4.396
Authors: Glenn D Prestwich; Isaac E Erickson; Thomas I Zarembinski; Michael West; William P Tew Journal: Acta Biomater Date: 2012-07-07 Impact factor: 8.947
Authors: Rebecca S Bartlett; Henry T Hoffman; Seth H Dailey; Jonathan M Bock; Sarah A Klemuk; Ryan W Askeland; Jan S Ahlrichs-Hanson; Andrew C Heaford; Susan L Thibeault Journal: Laryngoscope Date: 2013-08-19 Impact factor: 3.325
Authors: Joo Hyun Woo; Suzanne N King; Henry Hoffman; Seth Dailey; Sarah Wang; Michael B Christensen; Susan L Thibeault Journal: Otolaryngol Head Neck Surg Date: 2016-05-10 Impact factor: 3.497
Authors: Rebecca S Bartlett; Joel D Gaston; Tom Y Yen; Shuyun Ye; Christina Kendziorski; Susan L Thibeault Journal: Tissue Eng Part A Date: 2015-07-22 Impact factor: 3.845